@article{fdi:010073658,
  title = {{P}harmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries : a systematic review},
  author = {{A}twine, {D}. and {B}onnet, {M}aryline and {T}aburet, {A}. {M}.},
  editor = {},
  language = {{ENG}},
  abstract = {{A}ims{E}favirenz ({EFV}) and rifampicin-isoniazid ({RH}) are cornerstone drugs in human immunodeficiency virus ({HIV})-tuberculosis ({TB}) coinfection treatment but with complex drug interactions, efficacy and safety challenges. {W}e reviewed recent data on {EFV} and {RH} interaction in {TB}/{HIV} high-burden countries. {M}ethods{W}e conducted a systematic review of studies conducted in the high {TB}/{HIV}-burden countries between 1990 and 2016 on {EFV} pharmacokinetics during {RH} coadministration in coinfected patients. {T}wo reviewers conducted article screening and data collection. {R}esults{O}f 119 records retrieved, 22 were included (two conducted in children), reporting either {EFV} mid-dose or pre-dose concentrations. {I}n 19 studies, median or mean concentrations of {RH} range between 1000 and 4000ngml(-1), the so-called therapeutic range. {T}he proportion of patients with subtherapeutic concentration of {RH} ranged between 3.1 and 72.2%, in 12 studies including one conducted in children. {T}he proportion of patients with supratherapeutic concentration ranged from 19.6 to 48.0% in six adult studies and one child study. {F}ive of eight studies reported virological suppression >80%. {T}he association between any grade hepatic and central nervous system adverse effects with {EFV}/{RH} interaction was demonstrated in two and three studies, respectively. {T}he frequency of the {CYP}2{B}6 516{G}>{T} polymorphism ranged from 10 to 28% and was associated with higher plasma {EFV} concentrations, irrespective of ethnicity. {C}onclusions{A}nti-{TB} drug coadministration minimally affect the {EFV} exposure, efficacy and safety among {TB}-{HIV} coinfected {A}frican and {A}sian patients. {T}his supports the current 600mg {EFV} dosing when coadministered with anti-{TB} drugs.},
  keywords = {pharmacokinetics ; genetics and pharmacogenetics ; {HIV} ; {AIDS} < infectious diseases ; antiretrovirals < infectious diseases ; adverse drug reactions ; {AFRIQUE} ; {ASIE}},
  booktitle = {},
  journal = {{B}ritish {J}ournal of {C}linical {P}harmacology},
  volume = {84},
  numero = {8},
  pages = {1641--1658},
  ISSN = {0306-5251},
  year = {2018},
  DOI = {10.1111/bcp.13600},
  URL = {https://www.documentation.ird.fr/hor/fdi:010073658},
}